CD-801 for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This early-phase trial tests an experimental drug called CD-801 given through an IV for people with advanced liver cancer (HCC) that cannot be surgically removed and has not responded to or is not suitable for standard treatments. The goal is to see if CD-801 is safe and helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced liver cancer (HCC) that cannot be removed with surgery.
- You have tried or cannot have standard treatments, and your cancer has continued to grow or hasn't responded.
- You have at least one tumor that can be seen on a scan.
- Your liver, kidneys, and blood counts are good enough (your doctor will check these).
- You are not pregnant, and you are willing to use effective birth control during and for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
This trial tests SHR-8068 combined with adebrelimab and bevacizumab in people with advanced, hard-to-treat liver cancer. It aims to see whether this combination can shrink tumors and improve outcomes after standard treatments don’t work or aren’t an option.
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.